Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  breast cancer, male breast cancer
Trial Type:  Screening, Prevention
Trial Status:  Active
Results 1-25 of 66 for your search:
Start Over
National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations
Phase: Phase IV
Type: Screening
Status: Active
Age: 25 to 70
Sponsor: Other
Protocol IDs: DBCG07MRBRCA, NCT00413491
Multi-centre Clinical Trial on Hormone Replacement Treatment in China
Phase: Phase IV
Type: Prevention
Status: Active
Age: 40-to 60
Sponsor: Other
Protocol IDs: 2008BAI57B04, NCT01698164
Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women
Phase: Phase III
Type: Prevention
Status: Active
Age: 30 to 75
Sponsor: Other
Protocol IDs: GD-10-08, NCT00808522
Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: GAL 01, NCT01357772
LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)
Phase: Phase III
Type: Screening
Status: Active
Age: 5 to 71
Sponsor: Other
Protocol IDs: CSET2011/1748, NCT01464086
Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Status: Approved-not yet active
Age: 25 to 55
Sponsor: NCI, Other
Protocol IDs: A211102, U10CA031946, NCI-2013-00995, NCT01905046
Acquisition of Breast Mammography Images
Phase: Phase III
Type: Diagnostic, Health services research, Screening
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FMSU2013-004A, NCT02156258
Use of Hair to Diagnose Breast Cancer
Phase: Phase II, Phase I
Type: Screening
Status: Active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FT3.6k-2006, NCT00419679
Use of Hair to Diagnose the Presence of Breast Cancer
Phase: Phase II, Phase I
Type: Screening
Status: Active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FER2k, NCT00419900
Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 200806, NCT01425476
Changes in Biomarkers Using Prostaglandin Inhibitors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 200807-001, NCT01769625
Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers Undergoing Treatment for Breast Cancer
Phase: Phase II
Type: Prevention
Status: Active
Age: 30 to 90
Sponsor: Other
Protocol IDs: 102/07 (HT4351), NCT00496288
Statins and Breast Cancer Biomarkers
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 35 to 55
Sponsor: Other
Protocol IDs: V0407, CHRMS#: 05-059, NCT00914017
Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 25 and over
Sponsor: NCI, Other
Protocol IDs: 08218, R01CA140245-01, NCI-2010-01976, NCT01196936
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 21 to 49
Sponsor: Other
Protocol IDs: 12377, NCT01276704
Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0794, NCI-2012-00037, KG09 1020, NCT01471106
Assessment of Substitution of Focused Cliches and Ultrasound for Tomosynthesis
Phase: Phase II
Type: Screening
Status: Active
Age: 40 and over
Sponsor: Other
Protocol IDs: TOMOSEIN-1104, 2011-002051-34, NCT01612650
Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia
Phase: Phase II
Type: Prevention
Status: Active
Age: Not Specified
Sponsor: Other
Protocol IDs: Institut Jules Bordet, NCT01658956
NSAID Effects on Clinical and Imaging Breast Biomarkers
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 75 and under
Sponsor: Other
Protocol IDs: 1RO1 CA1615301A1, 12-0080-04, NCT01761877
Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00859, 12-474, 12-267, N01-CN-2012-00034, AAAK6752, MSKCC-12-267, H-33017, 2011-0766, MDA10-16-01, N01CN00034, N01CN35159, P30CA016672, NCT01849250
BRCA1/2 and Effect of Mifepristone on the Breast
Phase: Phase II
Type: Prevention
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-003703-35, NCT01898312
Acute Exercise Cardioprotection From Doxorubicin
Phase: Phase II
Type: Prevention
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: H13-03090, NCT02006979
Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk
Phase: Phase II
Type: Prevention
Status: Active
Age: 30 to 45
Sponsor: NCI, Other
Protocol IDs: 1300000596, 1R01CA172444-01A1, NCT02028221
Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 45 to 70
Sponsor: Other
Protocol IDs: STUDY00000703, NCT02101970
Breast Cancer - Anti-Progestin Prevention Study 1
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Approved-not yet active
Age: 25 to 45
Sponsor: Other
Protocol IDs: UHSM0315, NCT02408770
Start Over